Key result
Post-AMI beta-blocker use is linked to ~2-point lower 3-year mortality, confined to LVEF <50%.
Why the study?
The clinical benefit of beta-blockers across the continuous spectrum of LVEF after AMI remains uncertain, particularly in patients with mildly reduced systolic function.
Does baseline beta-blocker use reduce 3-year all-cause mortality in patients with acute myocardial infarction across the continuous range of LVEF?
Cohort (n=27,705)
Yes
Does baseline beta-blocker use reduce 3-year all-cause mortality in patients with acute myocardial infarction across the continuous range of LVEF?
In AMI patients, the 3-year survival benefit of beta-blockers diminishes continuously as LVEF increases and is only statistically significant in those with LVEF < 50%, supporting individualized therapy guided by LVEF.
Answers are grounded in this paper and cite their sources.
Observed survival benefit with beta-blockers should not yet change practice; leaves open confounding versus causal effect in observational data.
Background The clinical benefit of beta-blockers across the spectrum of left ventricular ejection fraction (LVEF) remains uncertain, particularly in patients with mildly reduced systolic function. Purpose We evaluated the association between baseline beta-blocker use and long-term survival across the continuous range of LVEF. Methods We included 27,705 patients (mean age 64 years, 76% male) from KAMIR, a nationwide AMI registry, between 2012 and 2020. Primary outcome was 3-year all-cause mortality. Confounding was addressed using inverse probability of treatment weighting (IPTW). Outcomes were analyzed using weighted Royston–Parmar flexible parametric survival models that allowed for time-varying treatment effects of beta-blocker use. The LVEF range associated with benefit of beta-blockers and number needed to treatment (NNT) were derived from absolute risk difference between groups. Results Overall, patients with beta-blockers (N=21,675) had higher 3-year survival than those without beta-blockers (N=6,030) (mortality 7.2% versus 9.4%; NNT = 45). The survival benefit diminished progressively with increasing LVEF, and was no longer statistically significant at LVEF ≥ 50%, though without evidence of harm. NNT was lowest in lower LVEF and increased with higher LVEF. Within the range of significant benefit of beta-blockers, NNT were 5, 10, 27, and 102 for for LVEF of 20%, 30%, 40%, and 50%, respectively. Conclusions The survival benefit of beta-blockers attenuated continuously with increasing LVEF, and was evident in patients with LVEF < 50% but not LVEF ≥ 50%. Our results support an individualized approach to beta-blocker therapy guided by LVEF rather than fixed categorical thresholds.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2026) conducted a cohort in Acute myocardial infarction (AMI) (n=27,705). Baseline beta-blocker use vs. No baseline beta-blocker use was evaluated on 3-year all-cause mortality (NNT 45). Baseline beta-blocker use after AMI was associated with lower 3-year all-cause mortality overall, with significant survival benefit limited to LVEF <50%.
Synapse has enriched 10 related papers. Consider them for comparative context: